Atopic Dermatitis News and Research

RSS
Atopic dermatitis is a long-term skin disease. "Atopic" refers to a tendency to develop allergy conditions. "Dermatitis" means swelling of the skin. Atopic dermatitis is most common in babies and children. But it can happen to anyone. People who live in cities and dry climates may be more likely to get this disease. When children with atopic dermatitis grow older, this problem can improve or go away. But the skin may stay dry and easy to irritate. At other times, atopic dermatitis is a problem in adulthood. You can't "catch" the disease or give it to other people.
Adults with eczema at greater risk of accidental bone fractures, other injuries

Adults with eczema at greater risk of accidental bone fractures, other injuries

Vanda reports total revenues of $14.8 million for third quarter 2014

Vanda reports total revenues of $14.8 million for third quarter 2014

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Milk fermented with probiotic dairy starter can improve skin of young women

Milk fermented with probiotic dairy starter can improve skin of young women

Vitamin D supplement significantly reduces symptoms of winter-related atopic dermatitis

Vitamin D supplement significantly reduces symptoms of winter-related atopic dermatitis

Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

EYLEA Injection gets approval in Japan for treatment of myopic CNV

EYLEA Injection gets approval in Japan for treatment of myopic CNV

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Study: Nervous system and stress affect inflammatory skin conditions

Study: Nervous system and stress affect inflammatory skin conditions

UCSF study: Acute psychological stress promotes healing in mouse models of different skin irritations

UCSF study: Acute psychological stress promotes healing in mouse models of different skin irritations

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Scientists identify genes that may help predict steroid responsiveness in people with EoE

Scientists identify genes that may help predict steroid responsiveness in people with EoE

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

NIH-funded study identifies genetic markers associated with eosinophilic esophagitis

NIH-funded study identifies genetic markers associated with eosinophilic esophagitis

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Study gives parents, doctors new options to treat children with eczema

Study gives parents, doctors new options to treat children with eczema

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Celsus’ expert highlights serious side effects of topical corticosteroids

Celsus’ expert highlights serious side effects of topical corticosteroids